JP2021518374A5 - - Google Patents

Info

Publication number
JP2021518374A5
JP2021518374A5 JP2020550082A JP2020550082A JP2021518374A5 JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP 2021518374 A5 JP2021518374 A5 JP 2021518374A5
Authority
JP
Japan
Prior art keywords
melanoma
pharmaceutical composition
composition according
dapanstril
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518374A (ja
JP7229565B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022770 external-priority patent/WO2019182981A1/en
Publication of JP2021518374A publication Critical patent/JP2021518374A/ja
Publication of JP2021518374A5 publication Critical patent/JP2021518374A5/ja
Application granted granted Critical
Publication of JP7229565B2 publication Critical patent/JP7229565B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550082A 2018-03-21 2019-03-18 メラノーマを治療するための方法 Active JP7229565B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
US62/645,999 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (3)

Publication Number Publication Date
JP2021518374A JP2021518374A (ja) 2021-08-02
JP2021518374A5 true JP2021518374A5 (cg-RX-API-DMAC7.html) 2022-03-15
JP7229565B2 JP7229565B2 (ja) 2023-02-28

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550082A Active JP7229565B2 (ja) 2018-03-21 2019-03-18 メラノーマを治療するための方法

Country Status (7)

Country Link
US (1) US11857529B2 (cg-RX-API-DMAC7.html)
EP (1) EP3768384B1 (cg-RX-API-DMAC7.html)
JP (1) JP7229565B2 (cg-RX-API-DMAC7.html)
CN (1) CN111867678B (cg-RX-API-DMAC7.html)
CA (1) CA3094307A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020009552A (cg-RX-API-DMAC7.html)
WO (1) WO2019182981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
EP4387729A4 (en) * 2021-08-19 2025-07-09 Olatec Therapeutics Inc METHODS OF TREATMENT OF PARKINSON'S DISEASE
WO2026035767A1 (en) * 2024-08-06 2026-02-12 Olatec Therapeutics, Inc. Methods for treating melanoma metastasis to liver and lungs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) * 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CA2875053C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
JP6185575B2 (ja) * 2012-06-05 2017-08-23 オラテック セラピューティクス リミティド ライアビリティ カンパニー 皮膚炎症性疾患の治療方法
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
EP3288980B1 (en) * 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
EP3589370A4 (en) * 2017-01-06 2020-11-18 Olatec Therapeutics LLC MULTIPLE SCLEROSIS TREATMENT METHOD
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
JP2017149726A5 (cg-RX-API-DMAC7.html)
IL292265B2 (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione)
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
IL273188B2 (en) Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor
RU2018109902A (ru) Виды комбинированной терапии для лечения рака
WO2018005519A3 (en) Cancer treatment combinations
JP2021535175A5 (cg-RX-API-DMAC7.html)
CN115916778A (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
MY204915A (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
EP4599894A3 (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
CN111699174A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
BR112021018169A2 (pt) Composto para o controle de diabetes de felinos
JP2023088996A5 (cg-RX-API-DMAC7.html)
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
RU2008148597A (ru) Фармацевтические комбинации
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP2020506169A5 (cg-RX-API-DMAC7.html)
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
JP2006528190A5 (cg-RX-API-DMAC7.html)